Rezūm水蒸气疗法与铥激光剜除术治疗大体积前列腺增生的多中心前瞻性比较研究
本研究为多中心前瞻性比较研究,纳入前列腺体积≥80 mL的BPH患者246例(ThuLEP组126例,Rezūm组120例),比较两种术式疗效与安全性。结果显示ThuLEP组IPSS总分在各随访点均显著低于Rezūm组(p<0.001),但差值未达最小临床重要差异;两组IIEF-EF均显著改善且无差异,Rezūm组MSHQ-EjD功能与困扰评分更优(p<0.001)。
要点
- ThuLEP与Rezūm均能显著改善大体积前列腺增生患者的排尿症状。
- ThuLEP在IPSS改善上统计优于Rezūm,但未达临床重要差异。
- Rezūm在射精功能与困扰评分上优于ThuLEP。
核心结论
- ThuLEP与Rezūm均能显著改善大体积前列腺增生患者的排尿症状。
- ThuLEP在改善下尿路症状上统计优于Rezūm,但未达临床重要差异。
研究设计与样本
- 多中心前瞻性比较研究,连续纳入前列腺体积≥80 mL接受ThuLEP或Rezūm的患者。
- 共纳入246例患者,其中ThuLEP组126例,Rezūm组120例。
- 评估时间点为基线及术后3、6、12个月。
主要发现
- ThuLEP组与Rezūm组平均(SD)前列腺体积分别为106.0(16.5)mL和101.4(14.8)mL(p=0.55)。
- ThuLEP组IPSS总分在各术后时间点均显著低于Rezūm组(p<0.001),但均值差异未达MCID。
- 两组IIEF-EF评分均显著改善(p<0.001),组间无显著差异。
- Rezūm组MSHQ-EjD功能与困扰评分在所有术后时间点均显著优于ThuLEP组(p<0.001)。
- 需再次干预止血或清除血块的Clavien-Dindo≥III级出血并发症:ThuLEP组5例(3.96%),Rezūm组1例(0.83%)(p=0.21)。
关键数值与推荐
- 主要结局为IPSS总分,次要结局包括IIEF-EF、MSHQ-EjD简表及Clavien-Dindo≥III级并发症。
- 前列腺体积≥80 mL为纳入标准。
临床怎么用
- 对于大体积前列腺增生患者,ThuLEP与Rezūm均可作为改善排尿症状的选项。
- 若患者特别关注射精功能保护,Rezūm可能具有优势。
- 两种术式在勃起功能改善方面无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the growing body of evidence supporting the use Rezūm in patients with benign prostatic hyperplasia (BPH) and large prostates, comparative studies with the current gold standard in this clinical setting are lacking. AIM: To compare the efficacy and safety of Rezūm and Thulium Laser Enucleation of the Prostate (ThuLEP) in patients with BPH and large prostates. METHODS: We conducted a multicenter prospective comparative study. Consecutive patients with prostate volume (PV) ≥ 80 mL undergoing ThuLEP or Rezūm were included. Patient evaluation was performed at baseline and at 3, 6, and 12 months after surgery. International Prostate Symptom Score (IPSS)-Total was chosen as the primary outcome, while International Index of Erectile Function (IIEF-EF), four-item version of Male Sexual Health Questionnaire (MSHQ-EjD Short Form), and postoperative complications Clavien-Dindo (CD) grade ≥ III were selected as the secondary outcomes. RESULTS: A total of 246 patients were enrolled (126 ThuLEP, 120 Rezūm). Mean (SD) PV was 106.0 (16.5) mL in the ThuLEP group and 101.4 (14.8) mL in the Rezūm group (p = 0.55). Mean (SD) IPSS-Total was statistically significantly lower in the ThuLEP group compared to the Rezūm group at every postoperative time point (p < 0.001); however, the difference between the mean values never reached the Minimal Clinically Important Difference (MCID). IIEF-EF score significantly improved in both groups (p < 0.001), with no significant difference between the two procedures. Significant differences in MSHQ-EjD Function and Bothers in favor of Rezūm were observed at all postoperative time points (p < 0.001). Bleeding with clots requiring reintervention (CD ≥ III) for hemostasis and evacuation occurred in 5 (3.96%) men undergoing ThuLEP and 1 (0.83%) man undergoing Rezūm (p = 0.21). CONCLUSIONS: Both ThuLEP and Rezūm significantly improve urinary symptoms in patients with BPH and large prostates. ThuLEP appears statistically but not clinically superior to Rezūm in improving LUTS.
引用
- Manfredi C, Spirito L, Quattrone C, et al. Rezūm water vapor therapy vs. thulium laser enucleation for the treatment of benign prostatic hyperplasia in patients with large prostates: a multicenter prospective comparative study. Prostate Cancer Prostatic Dis. 2025. PMID: 40229454. doi:10.1038/s41391-025-00971-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。